ARCHIVES

More Bad News for AVEO As Tivozanib Partner Bids Adieu

This article is from The Cancer Letter archive.

Vol. 39 No. 22 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Concept Of Contract Recompetitions Worth $5.1 Million A Year

July 10, 1981

In Brief: ONS Lectures Announced; Brennan To Retire As Michigan Cancer Foundation President

April 19, 1991

2015 Breakthrough Prize Winners Announced at Gala

November 14, 2014

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

Iniparib Plus Chemo Shows Benefit In Phase II Study

January 28, 2011

Phase III Cyramza Trial Meets OS Primary Endpoint

September 26, 2014